03 March 2011 14:53 [Source: ICIS news]
TORONTO (ICIS)--Amyris is expanding production of its biochemical farnesene through a contract manufacturing deal with a company in Spain, the US-based renewable chemicals firm said on Thursday.
Under the deal, ?xml:namespace>
The product would be owned and distributed by Amyris, it said. Amyris had similar arrangements with other firms, it added.
Amyris and Antibioticos already started test fermentation runs in January, and, based on the outcome, would proceed with expanded production, Amyris said.
“This agreement with Antibioticos should allow us to reach our target initial production levels and meet customer demand for our near-term product offerings,” John Melo, CEO of Amyris, said.
“We have been very impressed with the world-class technical expertise in aseptic fermentation at Antibioticos, and are looking forward to leverage this as we build up our commercial production capability,” he said.
He did not disclose capacity or financial details.
Potential applications for Amyris’ farnesene are in plastics additives, flavours and fragrance, lubricants, consumer product ingredients, and fuel.
Check out Doris de Guzman’s Green Chemicals Blog for views on sustainability issues
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
|ICIS news FREE TRIAL|
|Get access to breaking chemical news as it happens.|
|ICIS Global Petrochemical Index (IPEX)|
|ICIS Global Petrochemical Index (IPEX). Download the free tabular data and a chart of the historical index|